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Thiazolidinediones (TZD) have been shown to have
anti-diabetic effects including the ability to decrease
fasting hyperglycemia and hyperinsulinemia, in-
crease insulin-mediated glucose disposal rate (M)
and decrease hepatic glucose production, but the
mechanisms of action are not well established. To
determine whether a TZD (R-102380, Sankyo Com-
pany Ltd., Tokyo, Japan) could improve insulin
action on skeletal muscle glycogen synthase (GS),
the rate-limiting enzyme in glycogen synthesis, 4
insulin-resistant obese monkeys were given I mg/kg/
day R-102380 p.o. for a 6-week period. Skeletal
muscle GS activity and glucose 6-phosphate (G6P)
content were compared between pre-dosing and
dosing periods before and during the maximal
insulin-stimulation of a euglycemic hyperinsuline-
mic clamp.
Compared to pre-dosing, insulin-stimulated GS
activity and G6P content were increased by this
TZD: GS independent activity (p 0.02), GS total
activity (p 0.005), GS fractional activity (p 0.06)
and G6P content (p=0.02). The change in GS
activity induced by in vivo insulin (insulin-stimu-
lated minus basal) was also increased by this TZD:
GS independent activity (p 0.03) and GS fractional
activity (p 0.04).
We conclude that the TZD R-102380 improves
insulin action at the skeletal muscle in part by
increasing the activity of glycogen synthase. This
improvement in insulin sensitivity may be a key
factor in the anti-diabetic effect of the thiazolidine-
dione class of agents.
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INTRODUCTION
Thiazolidinediones have been shown to reduce
fasting and postprandial hyperglycemia and to
increase insulin-mediated glucose disposal rate
in type 2 diabetic humans,
[131 to decrease
fasting and postprandial concentrations of in-
sulin and triglycerides in obese insulin-resistant
rhesus monkeys,lJ to decrease hepatic glucose
production in diabetic miceI6J and in normal
rats,
[111 and to inhibit glucagon-stimulated gly-
cogen breakdown and gluconeogenesis in nor-
mal rat hepatocytes.I2 The mechanism of the
insulin sensitizing effect of the thiazolidine-
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diones is not known, although there is evidence
that they may act by regulating the expression of
genes involved in glucose and lipid metabolism
in adipose tissue and in skeletal muscle through
binding with the peroxisome proliferator-acti-
vated receptor-%7’ 21]
During a euglycemic hyperinsulinemic clamp
the skeletal muscle is the primary site for glucose
disposal, and glycogen storage is the primary
pathway of this glucose disposal. Insulin activa-
tion of skeletal muscle glycogen synthase, the
rate-limiting enzyme in glycogenesis, is strongly
related to insulin-mediated glucose disposal rate
in humans and in rhesus monkeys.3" 16] Insulin-
mediated skeletal muscle glycogen synthase
activity has been shown to be reduced in
insulin-resistant states. [3"161 Although several
studies have examined the effects of thiazolidi-
nediones on glycogen synthase activity in vi-
tro,[1"5"2] the effect of thiazolidinediones on in
vivo insulin action on skeletal muscle glycogen
synthase has not been previously reported.
The purpose of the present study was to
determine whether a thiazolidinedione could im-
prove in vivo insulin action during a eugly-
cemic hyperinsulinemic clamp by promoting
an increase in skeletal muscle glycogen synthase
activity in insulin-resistant monkeys.
MATERIALS AND METHODS
This chronic study of thiazolidinedione
treatment was carried out in four obese male
insulin-resistant rhesus monkeys (Macaca
mulatta) that had never received insulin treat-
ment. Baseline pre-dosing measurements in-
cluded 2 hour post-vehicle plasma glucose
and insulin determinations and a euglycemic
hyperinsulinemic clamp with tissue biopsies ob-
tained prior to the onset of the clamp (basal),
and during maximal insulin-stimulation. The
pre-dosing baseline measurements were report-
ed previously in a study which included the
determination of in vivo insulin action on liver,
subcutaneous and omental adipose tissue and on
skeletal muscle glycogen synthase activity. I141
Monkeys were then treated for 6 weeks with
R-102380 (Sankyo Company Ltd., Tokyo, Japan)
(1 mg/kg/day p.o.). At the end of this 6-week
period, the 2-hour post drug plasma glucose
and insulin concentrations were determined
and the euglycemic hyperinsulinemic clamp
with biopsies was repeated.
The euglycemic hyperinsulinemic clamp was
performed as previously described in these
animals.141 The glycogen synthase assay and
the glucose 6-phosphate assay were performed
as described previously.16’1sl The glucose 6-
phosphate Ka of glycogen synthase was deter-
mined as described previously, t191 Briefly, glyco-
gen synthase activity was measured in the
absence and in the presence of the following
glucose 6-phosphate concentrations: 0.10, 0.25,
0.50, 0.75, 1, 2.5, 5, 7.5 and 10mmol/1. The
glucose 6-phosphate Ka of glycogen synthase
(the apparent affinity of glycogen synthase for
glucose 6-phosphate) was then determined by
O
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plotting the glucose 6-phosphate concentration
against the glucose 6-phosphate concentration
divided by velocity (s/v against s plot),
tgl Total
protein was measured in the supernatant using
the Bradford method, t41
Data are expressed as mean 4-SE. Differences
in basal and insulin-stimulated values were
determined using a paired t-test.
The structure of the thiazolidinedione R-
102380 is shown in Figure 1.
RESULTS
The characteristics of the individual rhesus
monkeys before and at the end of the six-week
TZD treatment period are shown in Table I. For
these 4 adult insulin-resistant monkeys, consid-
ered as a group, administration of the TZD R-
102380, at a dose of I mg/kg/day for six weeks,
did not produce significant changes in body
weight, plasma glucose, plasma insulin, or
whole-body insulin-mediated glucose dispo-
sal rate. Nevertheless, it appears that the TZD
positively affected tissue insulin sensitivity in
every monkey, and that the individual monkeys
strongly differed in the ways in which the TZD
affected them. We suspect these individual
differences were dependent upon how far along
the progression toward overt diabetes each
monkey was at the time of study.
The monkey (J-8) that was hyperglycemic
prior to TZD treatment showed an improvement
in plasma glucose and an increase in plasma
insulin levels commensurate with an improve-
ment in the plasma insulin curve by reversing
the course followed during the natural progres-
sion toward overt type 2 diabetes,t8 This
monkey, reasonably considered the most dia-
betic of the group, showed the greatest improve-
ment in insulin sensitivity. A second monkey
(A-7), which was also declining toward diabetes
prior to TZD treatment, also showed a similar
increase in insulin sensitivity. Two normoglyce-
mic insulin-resistant monkeys (R-8 and S-8)
showed major declines in plasma insulin levels,
in accord with their position at an earlier phase
in the progression toward diabetes (at this early
stage, improvement in hyperinsuliemia is shown
by a lowering of plasma insulin concentrations);
thus, they showed improved beta-cell function,
although these two monkeys showed no meas-
urable improvement in insulin sensitivity, at
least as assessed by the euglycemic hyperinsu-
linemic clamp.
Basal skeletal muscle glycogen synthase activ-
ity for each individual monkey is presented in
Figure 2, with independent, total, and fractional
activity shown for the pre-dosing period and
during dosing. For the group as a whole, the
basal glycogen synthase activities were not
significantly effected by R-102380 (pre-R-102380
TABLE Characteristics of rhesus monkeys before and during R-102380
Body weight Glucose* Insulin*
Age Body fat (kg) (mmol/1) (pmol/1)
ID (Yr) (%) Pre Post Pre Post Pre Post Pre Post
M
(mg/kg FFM/min)
A-7 17 45.1 16.6 16.3 4.5 4.2 1464 1566 5.33 7.25
J-8 16 26.4 11.3 10.7 11.5 8.9 258 306 6.58 8.79
R-8 8 29.9 22.1 22.4 6.1 4.2 3636 1602 6.49 5.13
S-8 8 26.8 15.8 16.1 2.9 3.3 1692 558 5.25 4.67
Plasma glucose and insulin determinations were made during the pre-treatment period 2 hours following administration of
vehicle and during dosing period 2 hours after the monkey received the same vehicle containing I mg/kg R-102380. whole-
body insulin-mediated glucose disposal rate.9
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FIGURE 2 Basal and insulin-stimulated skeletal muscle glycogen synthase activities before and after 6 weeks of treatment
with R-102380 in 4 obese insulin-resistant monkeys. The mean insulin-stimulated activities before vs. during R-102380 were
significantly different for independent (p 0.02) and for total (p 0.005) activity. The mean insulin effect (insulin-stimulated
minus basal) before vs. during R-102380 was significantly different for independent p 0.03) and for fractional p 0.04) activity.THIAZOLIDINEDIONE EFFECT ON GLYCOGEN SYNTHASE IN MONKEYS 199
VS. during R-102380: independent activity,
0.73 4- 0.12 vs. 1.01 4- 0.17 nmol/min.mg pro-
tein, p 0.11; total activity, 11.29 4- 2.22 vs.
22.60 4- 3.34nmol/min.mg protein, p 0.07;
fractional activity, 7.5 4- 2.3 vs. 4.8 4- 1.4%,
p=0.08). All individual monkeys showed an
increase in both basal glycogen synthase inde-
pendent activity and basal glycogen synthase
total activity; however, the individual monkeys
varied in the magnitudes of their responses,
thus, preventing significance by the usual paired
tests. The small but consistent increases in
basal glycogen synthase independent activity
were accompanied by much larger increases in
total glycogen synthase activity, and thus, the
glycogen synthase fractional activity (propor-
tion of glycogen synthase in the active form
[independent] relative to total glycogen
synthase) was reduced during treatment relative
to pre-treatment.
Under insulin stimulation during a euglyce-
mic hyperinsulinemic clamp, skeletal muscle
glycogen synthase activity was also examined,
as shown in Figure 2. For the group as a
whole, the TZD significantly increased insulin-
stimulated glycogen synthase activity: insulin-
stimulated glycogen synthase independent
activity was increased 3 fold (1.54-0.7 vs.
4.4 4- 1.3nmol/min/mg protein, p 0.02),
and total glycogen synthase activity was also
increased nearly 3 fold (9.6 4- 1.1 vs.
26.3 4- 1.7nmol/min/mg protein, p 0.005).
Glycogen synthase fractional activity under insu-
lin stimulation tended to be increased (14 4-6
vs. 184-7%, p=0.06). As for basal glycogen
synthase activity, every individual monkey
showed an increase in insulin-stimulated
glycogen synthase activity-independent, total,
and fractional activity, but the magnitude of
the increment induced by the TZD varied
across animals.
R-102389 significantly enhanced insulin ac-
tion (insulin-stimulated minus basal) on glyco-
gen synthase independent (0.76 4- 0.62 vs.
3.35 4- 1.23nmol/min/mg protein, p 0.03)
and fractional activities (6.8 4-3.9 vs. 13.34-
5.5%, p=0.04), but had no significant effect
on the change in glycogen synthase total activity
in response to insulin (-1.67 4- 3.31 vs. 3.74 4-
2.00, p=0.24). The magnitude of the TZD
effect on independent glycogen synthase activ-
ity was much greater (about 3 fold) under
insulin stimulation than under the basal condi-
tion. The greatest absolute increase in glycogen
synthase independent activity and in glycogen
synthase fractional activity with R-102380 treat-
ment was observed in the most diabetic monkey
(J-8), the monkey that also showed the greatest
increase in whole-body insulin sensitivity as
measured by the euglycemic hyperinsulinemic
clamp.
Basal glucose 6-phosphate content was not
significantly effected by R-102380 (0.47 4- 0.17 vs.
0.734-0.15 nmol/mg dry weight, p=0.13).
Glucose 6-phosphate content under insulin-
stimulated conditions was significantly higher
during dosing (0.43 4- 0.08 nmol/mg dry
weight) than before dosing (0.27 4- 0.09nmol/
mg dry weight) (p 0.02) (Fig. 3).
Neither the basal, insulin-stimulated nor in-
sulin effect on the glucose 6-phosphate Ka of
glycogen synthase were significantly effected
by R-102380 (basal, 2.344-0.94 vs. 2.78 4-
0.85 mmol/1, p-- 0.13; insulin-stimulated, 1.15 4-
0.45 vs. 0.734-0.19mmol/1, p=0.28; insulin-
stimulated minus basal, 1.19 4- 1.02 vs.
-2.05 4-0.73 mmol/1, p=0.17) (Fig. 3). Basal vs.
insulin-stimulated glucose 6-phosphate Ka of
glycogen synthase during dosing approached
significance (p 0.07).
The total basal protein concentrations before
R-102380 and during R-102380 administration
were 0.89 4- 0.12 vs. 1.23 4- 0.09 mg/ml, respec-
tively (p 0.09). The total protein concentrations
under insulin-stimulated conditions before R-
102380 and during R-102380 administration
were 0.94 4- 0.04 vs. 1.16 4- 0.10mg/ml, respec-
tively (p 0.11).200 H.K. ORTMEYER et al.
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FIGURE 3 Basal and insulin-stimulated skeletal muscle glucose 6-phosphate content and glucose 6-phosphate Ka of glycogen
synthase before and after 6 weeks of treatment with R-102380. The mean before vs. during R-102380 was significantly different
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DISCUSSION
Insulin activation of skeletal muscle glycogen
synthase by dephosphorylation is a good meas-
ure of insulin sensitivity. In normal rhesus
monkeys, in vivo insulin during a euglycemic
hyperinsulinemic clamp caused a significant
increase in the independent activity of skeletal
muscle glycogen synthase without changing total
glycogen synthase activity. I161 This resulted in a
significant increase in the fractional activity of
the enzyme. In addition, in vivo insulin during a
euglycemic hyperinsulinemic clamp resulted in a
significant decrease in the glucose 6-phosphate
Ka of glycogen synthase in normal (ad libitum-
fed) rhesus monkeys,t171 which is consistent with
an increase in dephosphorylation of the enzyme.
In obese hyperinsulinemic and type 2 diabetic
monkeys, the effect of insulin to increase glyco-
gen synthase independent activity was signifi-
cantly less than that of the normal monkeys.16
The effect of insulin to covalently activate muscle
glycogen synthase was strongly related to whole-
body insulin-mediated glucose disposal rate in
these monkeys. I161
In the present study of insulin-resistant rhesus
monkeys, 6 weeks of treatment with a thiazoli-
dinedione (R-102380) resulted in a significant
increase in insulin sensitivity as measured by an
increase in insulin action on skeletal muscle
glycogen synthase independent and fractional
activity. A similar finding has been reported on
the effect of the thiazolidinedione AD-5075 to
increase in vitro insulin stimulation of rat adipose
tissue glycogen synthase.I1 In that study, AD-
5075 was added to adipose tissue in vitro and the
tissue cultured for 5hours. AD-5075 caused a
significant increase in basal independent glyco-
gen synthase activity as well as in in vitro insulin-
stimulated independent glycogen synthase
activity. Total glycogen synthase activity was
not significantly affected by AD-5075, either in
the basal or insulin-stimulated conditions, tll
In another study of in vitro thiazolidinedione
effect on glycogen synthase, troglitazone was
added to skeletal muscle cultures of type 2
diabetic subjects.I2l Troglitazone was shown to
significantly increase glycogen synthase frac-
tional activity under in vitro insulin stimulation
compared to basal activity. Although the effect
of troglitazone on total glycogen synthase
activity was not reported in that study, chronic
troglitazone did not effect either mRNA or
protein concentrations of glycogen synthase.21
In the present study, 6 weeks of treatment
with R-102380 did not cause a significant change
in the glucose 6-phosphate Ka of glycogen syn-
thase, either during basal or insulin-stimulated
conditions. This is in contrast to an in vitro study
in which the thiazolidinedione CS-045 was
added to cultured liver cells. I51 In that study,
the addition of CS-045 caused a 3 fold decrease
in the glucose 6-phosphate Ka of glycogen
synthase; however, CS-045 also caused a signi-
ficant decrease in total glycogen synthase activ-
ity in the Hep G2 cells.I5 In addition, CS-045
did not increase glycogen synthase indepen-
dent activity above the increase seen in the pre-
sence of in vitro insulin in either Hep G2 or
BC3H-1 cells.5
In the present study, the most profound effect
of R-102380 was an increase in skeletal muscle
glycogen synthase total activity during the
euglycemic hyperinsulinemic clamp. This sug-
gests that administration of R-102380 increased
glycogen synthase protein expression in the
presence of in vivo insulin. In vivo insulin during
a euglycemic hyperinsulinemic clamp has not
been shown to increase skeletal muscle glycogen
synthase total activity in normal, prediabetic or
diabetic monkeys or in chronically calorie-
restricted monkeys,
[14-16] neither has it been
shown to increase protein expression or mRNA
expression in humans. [12" 22, 23]
In summary, the thiazolidinedione R-102380
improves in vivo insulin action on skeletal
muscle glycogen synthase in insulin-resistant
rhesus monkeys; this may be an important
mechanism by which thiazolidinediones im-
prove insulin sensitivity. The effect of R-102380202 H.K. ORTMEYER et al.
to increase glycogen synthase total activity dur-
ing a euglycemic hyperinsulinemic clamp war-
rants the future investigation of the effect of
thiazolidinediones on skeletal muscle glycogen
synthase protein and mRNA expression.
Acknowledgements
The authors would like to thank the following
people for their excellent technical support of
this study: Theresa Alexander, Wallace Evans,
Jr., Karen Brocklehurst, Alana Dunevant and
Teerin Meckmongkol.
References
[1] Berger, J., Biswas, C., Hayes, N., Ventre, J., Wu, M. and
Doebber, T. W. (1996). An antidiabetic thiazolidine-
dione potentiates insulin stimulation of glycogen
synthase in rat adipose tissue. Endocrinology, 137,
1984 1990.
[2] Blackmore, P. F., McPherson, R. K. and Stevenson,
R. W. (1993). Actions of the novel antidiabetic agent
englitazone in rat hepatocytes. Metabolism, 42, 1583-
1587.
[3] Bogardus, C., Lillioja, S., Stone, K. and Mort, D. (1984).
Correlation between muscle glycogen synthase activity
and in vivo insulin action in man. J. Clin. Invest., 73,
1185-1190.
[4] Bradford, M. M. (1976). A rapid and sensitive method
for the quantitation of microgram quantities of protein
utilizing the principle of protein-dye binding. Anal.
Biochem., 72, 248- 254.
[5] Ciaraldi, T. P., Gilmore, A., Olefsky, J. M., Goldberg, M.
and Heidenreich, K. A. (1990). In vitro studies on the
action of CS-045, a new antidiabetic agent. Metabolism,
39, 1056-1062.
[6] Fujiwara, T., Okuno, A., Yoshioka, S. and Horikoshi, H.
(1995). Suppression of hepatic gluconeogenesis in long-
term Troglitazone treated diabetic KK and C57BL/KsJ-
db/db mice. Metabolism, 44, 486-490.
[7] Hallakou, S., Doar6, L., Foufelle, F., Kergoat, M.,
Guerre-Millo, M., Berthault, M. -F., Dugail, I., Morin,
J., Auwerx, J. and Ferr6, P. (1997). Pioglitazone induces
in vivo adipocyte differentiation in the obese Zucker
fa/fa rat. Diabetes, 46, 1393-1399.
[8] Hansen, B. C. and Bodkin, N. L. (1986). Heterogeneity
of insulin responses: phases in the continuum leading
to non-insulin-dependent diabetes mellitus. Diabetolo-
gia, 29, 713-719.
[9] Henderson, P., Statistical analysis of enzyme kinetic
data. In: Enzyme Assays: A Practical Approach, edited by
Eisenthal, R. and Danson, M. Oxford: IRL press, 1993,
pp. 277-316.
[10] Kemnitz, J., Elson, D., Roecker, E., Baum, S., Bergman,
R. and Meglasson, M. (1994). Pioglitazone increases
insulin sensitivity, reduces blood glucose, insulin, and
lipid levels, and lowers blood pressure in obese,
insulin-resistant rhesus monkeys. Diabetes, 43, 204-211.
[11] Lee, M. K. and Olefsky, J. M. (1995). Acute effects of
troglitazone on in vivo insulin action in normal rats.
Metabolism, 44, 1166 1169.
[12] Mandarino, L. J., Printz, R. L., Cusi, K. A., Kinchington,
P., O’Doherty, R. M., Osawa, H., Sewell, C., Consoli, A.,
Granner, D. K. and DeFronzo, R. A. (1995). Regulation
of hexokinase II and glycogen synthase mRNA,
protein, and activity in human muscle. Am. J. Physiol.,
269, E701 E708.
[13] Mimura, K., Umeda, F., Hiramatsu, S., Taniguchi, S.,
Ono, Y., Nakashima, N., Kobayashi, K., Masakado, M.,
Sako, Y. and Nawata, H. (1994). Effects of a new oral
hypoglycemic agent (CS-045) on metabolic abnormala-
ties and insulin resistance in type 2 diabetes. Diabetic
Medicine, 11, 685-691.
[14] Ortmeyer, H. K. and Bodkin, N. L. (1998). Lack of
defect in insulin action on hepatic glycogen synthase
and phosphorylase in insulin-resistant monkeys. Am. J.
Physiol., 274, G1005-G1010.
[15] Ortmeyer, H. K., Bodkin, N. L. and Hansen, B. C.
(1994). Chronic caloric restriction alters glycogen
metabolism in rhesus monkeys. Obes. Res., 2, 549-555.
[16] Ortmeyer, H. K., Bodkin, N. L. and Hansen, B. C.
(1993). Insulin-mediated glycogen synthase activity in
muscle of spontaneously insulin-resistant and diabetic
rhesus monkeys. Am. J. Physiol., 265, R552-R558.
[17] Ortmeyer, H. K., Bodkin, N. L. and Hansen, B. C.
(1999). Paradoxical phosphorylation of skeletal muscle
glycogen synthase by in vivo insulin in very lean young
adult rhesus monkeys. Annals New York Academy of
Sciences, 892, 247-260.
[18] Ortmeyer, H. K., Bodkin, N. L. and Hansen, B. C.
(1994). Relationship of skeletal muscle glucose-6-phos-
phate to glucose disposal rate and glycogen synthase
activity in insulin-resistant and non-insulin-dependent
diabetic rhesus monkeys. Diabetologia, 37, 127-133.
[19] Ortmeyer, H. K., Huang, L., Larner, J. and Hansen,
B. C. (1998). Insulin unexpectedly increases the glucose
6-phosphate Ka of skeletal muscle glycogen synthase
in calorie-restricted monkeys. J. Basic Clin. Physiol.
Pharmacol., 9, 309- 323.
[20] Park, K. S., Ciaraldi, T. P., Abrams-Carter, L., Mudaliar,
S., Nikoulina, S. E. and Henry, R. R. (1998). Tro-
glitazone regulation of glucose metabolism in human
skeletal muscle cultures from obese type II diabetic
subjects. J. Clin. Endocrinol. Metab., 83, 1636-1643.
[21] Park, K. S., Ciaraldi, T. P., Lindgren, K., Abrams-Carter,
L., Mudaliar, S., Nikoulina, S. E., Tufari, S. R.,
Veerkamp, J. H., Vidal-Puig, A. and Henry, R. R.
(1998). Troglitazone effects on gene expression in
human skeletal muscle of type II diabetes involve
up-regulation of peroxisome proliferator-activated
receptor-gamma. J. Clin. Endocrinol. Metab., 83,
2830-2835.
[22] Schalin-J/intti, C., Laurila, E., L6fman, M. and Groop,
L. C. (1995). Determinants of insulin-stimulated ske-
letal muscle glycogen metabolism in man. European
Journal of Clinical Investigation, 25, 693-698.
[23] Vestergaard, H., Bjorbaek, C., Andersen, P. H., Bak,
J. F. and Pedersen, O. (1991). Impaired expression of
glycogen synthasemRNA in skeletal muscle ofNIDDM
patients. Diabetes, 40, 1740-1745.